Simplify Logo
Beeline Medicines

Beeline Medicines

Clinical-stage biotech developing precision autoimmune therapies

Associate Director - Clinical Data Management

Full-Time
$181k - $235k/yr

+ Annual bonus + Long-term incentive award + Equity

Senior
Bachelor's
Boston, MA, USA
Hybrid

At least two days on-site per week, currently Tuesday and Wednesday; additional on-site days may be required.

About the job

Requirements
  • A bachelor's degree in Life Sciences, Health Sciences, Computer Science, or a related discipline, or equivalent education and experience.
  • At least 7 years of progressive clinical data management experience within the pharmaceutical, biotechnology, or contract research organization industry.
  • Experience managing clinical data management activities across Phase I–III clinical development, including late-stage or registration-enabling trials.
  • Experience managing contract research organization relationships and overseeing outsourced clinical data management activities.
  • Proficiency with electronic data capture platforms such as Medidata Rave and Veeva Vault EDC, and with CDISC standards including CDASH, SDTM, and ADaM.
  • Working knowledge of data cleaning, query management, and database lock processes.
  • Proficiency with medical coding dictionaries including MedDRA and WHO Drug, and with coding conventions.
  • Familiarity with centralized data review methodologies, data visualizations, review tools for identifying data quality trends, and risk-based monitoring approaches.
  • Ability to lead cross-functional study teams and manage contract research organization performance without direct reporting authority.
  • Strong written and verbal communication for cross-functional and vendor collaboration.
  • Ability to present data management status and risks to program leadership.
  • Ability to translate technical data issues into clear, actionable summaries for non-clinical-data-management stakeholders.
  • Ability to facilitate technical system design discussions and data quality oversight review meetings with internal and external cross-functional team members.
Responsibilities
  • Oversee the development and review of Data Management Plans, case report form/electronic case report form design specifications, data validation plans, custom listings and reports, and data cleaning plans.
  • Oversee electronic data capture and other clinical data systems builds supporting protocol objectives, site-level and patient-level data-entry workflows, user acceptance testing, database releases, mid-study updates, interim snapshots, and database lock activities.
  • Monitor clinical data quality, study metrics, and key performance indicators to ensure timely and accurate data cleaning, discrepancy management, medical coding, and reconciliation of external data sources such as central laboratories, electronic clinical outcome assessments, and safety data.
  • Participate in internal and external cross-functional study team meetings by communicating study status, identifying risks to timelines, data quality, and regulatory compliance, and recommending mitigation strategies.
  • Ensure clinical data management activities comply with ICH E6(R3) Good Clinical Practice guidelines, 21 CFR Parts 11 and 312, data security and privacy requirements such as GDPR and HIPAA, and other applicable global regulatory requirements.
  • Contribute to process improvement initiatives, standard operating procedure development, and data management standards across programs.
  • Support preparation for regulatory inspections and audits by maintaining complete documentation of data management activities and sponsor oversight.
  • Ensure regular documentation filings into the Trial Master File.
  • Perform other assigned duties and responsibilities.
Desired Qualifications
  • Experience in immunology or autoimmune therapeutic areas.

About the company

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...